Krystal Biotech is trading 4.09% down now at $356.29 on September 4, 2026, with no fresh company-specific announcement, earnings release, regulatory action, or analyst event found to clearly explain the decline.
- The latest notable catalyst was the August 3 earnings report, when revenue missed expectations despite an earnings beat.
- Broader markets are modestly lower following stronger employment data and increased rate-hike expectations, but the move is not large enough to clearly explain this stock-specific decline.